{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:36:45Z","timestamp":1790642205625,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T00:00:00Z","timestamp":1561420800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T00:00:00Z","timestamp":1561420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s40261-019-00805-5","type":"journal-article","created":{"date-parts":[[2019,6,25]],"date-time":"2019-06-25T19:33:38Z","timestamp":1561491218000},"page":"857-864","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Drug\u2013Drug Interactions in Children and Adolescents Receiving Ledipasvir\/Sofosbuvir for the Treatment of Hepatitis C Virus Infection"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2398-5231","authenticated-orcid":false,"given":"Hala Mohsen","family":"Abdullatif","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rania","family":"Ramzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Engy Adel","family":"Mogahed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyne Morcos","family":"Ghobrial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basma Abd","family":"El Rasheed Abd El Zaher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mona S.","family":"El Raziky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanaa Mostafa","family":"El-Karaksy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,25]]},"reference":[{"key":"805_CR1","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","volume":"370","author":"KV Kowdley","year":"2014","unstructured":"Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, ION-3 Investigators, et al. Ledipasvir and sofosbuvir for 8 or 12\u00a0weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879\u201388.","journal-title":"N Engl J Med."},{"key":"805_CR2","unstructured":"US FDA. FDA news release: FDA approves two hepatitis C drugs for pediatric patients. 2017. \n                    www.fda.gov\/news-events\/press-announcements\/fda-approves-two-hepatitis-c-drugs-pediatric-patients\n                    \n                  . Accessed 10 May 2019."},{"key":"805_CR3","unstructured":"European Medicines Agency. Harvoni (ledipasvir\/sofosbuvir) film-coated tablets: EU summary of product characteristics. 2014. \n                    http:\/\/www.ema.europa.eu\/\n                    \n                  . Accessed 10 May 2019."},{"issue":"67","key":"805_CR4","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1093\/cid\/ciy585","volume":"2018","author":"Aasld-Idsa, HCV Guidance Panel. Hepatitis C guidance","year":"2018","unstructured":"Aasld-Idsa, HCV Guidance Panel. Hepatitis C guidance. update: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C virus infection. Clin Infect Dis. 2018;2018(67):1477\u201392.","journal-title":"Clin Infect Dis"},{"key":"805_CR5","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69:461\u2013511.","journal-title":"J Hepatol"},{"key":"805_CR6","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1097\/MPG.0000000000001872","volume":"66","author":"G Indolfi","year":"2018","unstructured":"Indolfi G, Hierro L, Dezsofi A, Jahnel J, Debray D, Hadzic N, et al. Treatment of chronic hepatitis C virus infection in children: a position paper by the Hepatology Committee of European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. 2018;66:505\u201315.","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"805_CR7","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/hep.27920","volume":"63","author":"T Dick","year":"2016","unstructured":"Dick T, Lindberg L, Ramirez D, Charlton M. A clinician\u2019s guide to drug-drug interactions with direct-acting antiviral agents for the treatment of hepatitis C viral infection. Hepatology. 2016;63:634\u201343.","journal-title":"Hepatology"},{"key":"805_CR8","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/cid\/civ973","volume":"62","author":"C Siederdissen","year":"2016","unstructured":"Siederdissen C, Maasoumy B, Marra F, Deterding K, Port K, Manns M, et al. Drug\u2013drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort. Clin Infect Dis. 2016;62:561\u20137.","journal-title":"Clin Infect Dis"},{"key":"805_CR9","unstructured":"Gilead Sciences Inc. Harvoni (ledipasvir and sofosbuvir) tablets for oral use: US prescribing information. 2015. \n                    http:\/\/www.harvoni.com\/\n                    \n                  . Accessed 10 May 2019."},{"key":"805_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1517\/17425255.2011.558839","volume":"7","author":"I Jimenez-Nacher","year":"2011","unstructured":"Jimenez-Nacher I, Alvarez E, Morello J, Rodriguez-N\u00f3voa S, de Andr\u00e9s S, Soriano V. Approaches for understanding and predicting drug interactions in HIV infected patients. Expert Opin Drug Metab Toxicol. 2011;7:457\u201377.","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"805_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.2165\/00003088-200038010-00003","volume":"38","author":"GK Dresser","year":"2000","unstructured":"Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2000;38:41\u201357.","journal-title":"Clin Pharmacokinet"},{"key":"805_CR12","doi-asserted-by":"publisher","first-page":"600","DOI":"10.2174\/138945011795378504","volume":"12","author":"B Marquez","year":"2011","unstructured":"Marquez B, Van Bambeke F. ABC multidrug transporters: target for modulation of drug pharmacokinetics in drug-drug interactions. Curr Drug Targets. 2011;12:600\u201320.","journal-title":"Curr Drug Targets"},{"key":"805_CR13","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.1007\/s40262-018-0654-5","volume":"57","author":"P German","year":"2018","unstructured":"German P, Mathias A, Brainard DM, Kearney BP. Drug-drug interaction profile of the fixed-dose combination tablet regimen ledipasvir\/sofosbuvir. Clin Pharmacokinet. 2018;57:1369\u201383.","journal-title":"Clin Pharmacokinet"},{"key":"805_CR14","unstructured":"University of Liverpool. 2010. HEP drug interactions. 2010. \n                    http:\/\/www.hep-druginteractions.org\n                    \n                  . Accessed 4 May 2018."},{"key":"805_CR15","unstructured":"Lexicomp\u00ae. Interactions. \n                    http:\/\/www.wolterskluwercdi.com\/lexicomp-online\/user-guide\/tools-interactions\/\n                    \n                  . Accessed 3 Apr 2018."},{"key":"805_CR16","unstructured":"Medscape. Drug interaction checker. 2018. \n                    https:\/\/reference.medscape.com\/drug-interactionchecker\n                    \n                  . Accessed 3 Apr 2018."},{"key":"805_CR17","unstructured":"Lexicomp\u00ae. Lexi-interact data fields. 2018. \n                    http:\/\/webstore.lexi.com\/Information\/Product-Information\/Lexi-Interact-Fields\n                    \n                  . Accessed 3 Apr 2018."},{"key":"805_CR18","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1093\/cid\/civ973","volume":"62","author":"C H\u00f6ner Zu Siederdissen","year":"2016","unstructured":"H\u00f6ner Zu Siederdissen C, Maasoumy B, Marra F, Deterding K, Port K, et al. Drug-drug interactions with novel all oral interferon-free antiviral agents in a large real-world cohort. Clin Infect Dis. 2016;62:561\u20137.","journal-title":"Clin Infect Dis."},{"key":"805_CR19","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1111\/apt.13769","volume":"44","author":"J Vermehren","year":"2016","unstructured":"Vermehren J, Peiffer KH, Welsch C, Grammatikos G, Welker MW, Weiler N, et al. The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2016;44:856\u201365.","journal-title":"Aliment Pharmacol Ther"},{"key":"805_CR20","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.3748\/wjg.v23.i9.1618","volume":"23","author":"JA Langness","year":"2017","unstructured":"Langness JA, Nguyen M, Wieland A, Everson GT, Kiser JJ. Optimizing hepatitis C virus treatment through pharmacist interventions: identification and management of drug-drug interactions. World J Gastroenterol. 2017;23:1618\u201326.","journal-title":"World J Gastroenterol"},{"key":"805_CR21","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1177\/1060028018766507","volume":"52","author":"AA Ottman","year":"2018","unstructured":"Ottman AA, Townsend ML, Hashem MG, DiMondi VP, Britt RB. Incidence of drug interactions identified by clinical pharmacists in veterans initiating treatment for chronic hepatitis C infection. Ann Pharmacother. 2018;52:763\u20138.","journal-title":"Ann Pharmacother"},{"key":"805_CR22","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1097\/MPG.0000000000002101","volume":"67","author":"HM El-Karaksy","year":"2018","unstructured":"El-Karaksy HM, Mogahed EA, Abdullatif H, Ghobrial C, El-Raziky MS, Eel-Koofy N, et al. Sustained viral response in genotype 4 chronic HCV infected children and adolescents treated with sofosbuvir\/ledipasvir. J Pediatr Gastroenterol Nutr. 2018;67:626\u201330.","journal-title":"J Pediatr Gastroenterol Nutr"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00805-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-019-00805-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-019-00805-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T23:33:05Z","timestamp":1592955185000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-019-00805-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,25]]},"references-count":22,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["805"],"URL":"https:\/\/doi.org\/10.1007\/s40261-019-00805-5","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,25]]},"assertion":[{"value":"25 June 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No funding was received for the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Hala Mohsen Abdullatif, Rania Ramzi, Engy Adel Mogahed, Carolyne Morcos Ghobrial, Basma Abd El Rasheed Abd El Zaher, Mona S. El Raziky, and Hanaa Mostafa El-Karaksy have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}